Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia

Patent metadata

Field	Value
Publication number	US-10501427-B2
Application number	US-201816146625-A
Country	US
Kind code	B2
Filing date	Sep 28, 2018
Priority date	Jun 20, 2011
Publication date	Dec 10, 2019
Grant date	Dec 10, 2019

Abstract

The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.

First claim

What is claimed:

1. A hydrogen fumarate salt of a deuterium enriched compound of formula Y:

wherein,
R 1 -R 10 are independently hydrogen or deuterium, wherein at least two of R 1 -R 10 are deuterium.

2. The hydrogen fumarate salt of claim 1 , wherein the compound is

3. The hydrogen fumarate salt of claim 1 , wherein the compound is

4. The hydrogen fumarate salt of claim 1 , wherein the compound is

5. The hydrogen fumarate salt of claim 1 , wherein the compound is

6. The hydrogen fumarate salt of claim 1 , wherein the compound is

Assignees

• H Lundbeck As

Inventors

• Jorgensen Morten
• Andersen Peter Hongaard
• Jensen Klaus Gjervig

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/24

  Antidepressants · CPC title

• A61P25/18

  Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61K31/554

  having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem · CPC title